Gain Therapeutics Valuation
| GANX Stock | USD 3.39 0.22 6.94% |
At this time, the firm appears to be undervalued. Gain Therapeutics retains a regular Real Value of $4.66 per share. The prevalent price of the firm is $3.39. Our model calculates the value of Gain Therapeutics from evaluating the firm fundamentals such as Shares Outstanding of 16.22 M, return on equity of -1.42, and Return On Asset of -0.65 as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors encourage acquiring undervalued assets and dropping overvalued assets since, at some point, asset prices and their ongoing real values will come together. Key fundamental drivers impacting Gain Therapeutics' valuation include:
Price Book 3.9975 | Enterprise Value 36 M | Enterprise Value Ebitda (1.56) | Price Sales 925.9162 | Enterprise Value Revenue 625.4774 |
Undervalued
Today
Please note that Gain Therapeutics' price fluctuation is relatively risky at this time. Calculation of the real value of Gain Therapeutics is based on 3 months time horizon. Increasing Gain Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Gain Therapeutics is useful when determining the fair value of the Gain stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Gain Therapeutics. Since Gain Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Gain Stock. However, Gain Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.39 | Real 4.66 | Target 9.2 | Hype 3.2 | Naive 3.44 |
The real value of Gain Stock, also known as its intrinsic value, is the underlying worth of Gain Therapeutics Company, which is reflected in its stock price. It is based on Gain Therapeutics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Gain Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Gain Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Gain Therapeutics helps investors to forecast how Gain stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Gain Therapeutics more accurately as focusing exclusively on Gain Therapeutics' fundamentals will not take into account other important factors: Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Gain Therapeutics' intrinsic value based on its ongoing forecasts of Gain Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Gain Therapeutics' closest peers. When choosing an evaluation method for Gain Therapeutics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.
Gain Therapeutics Investments |
|
Gain Valuation Trend
Knowing Gain Therapeutics' actual value is paramount for traders to make sound investment determinations. Gain Therapeutics' real value is not only important for the investor to make better decisions but also for a more accurate overall view of Gain Therapeutics' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Gain Therapeutics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
Gain Market Cap
Gain Therapeutics is rated # 5 in market capitalization category among related companies. Market capitalization of Health Care industry is currently estimated at about 926.26 Million. Gain Therapeutics holds roughly 51.12 Million in market capitalization claiming about 6% of equities under Health Care industry.Gain Therapeutics Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Gain Therapeutics's current stock value. Our valuation model uses many indicators to compare Gain Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gain Therapeutics competition to find correlations between indicators driving Gain Therapeutics's intrinsic value. More Info.Gain Therapeutics is one of the top stocks in price to book category among related companies. It is one of the top stocks in price to sales category among related companies fabricating about 231.62 of Price To Sales per Price To Book. At this time, Gain Therapeutics' Price To Sales Ratio is fairly stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Gain Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Gain Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Gain Therapeutics' earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Gain Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Gain Therapeutics and how it compares across the competition.
About Gain Therapeutics Valuation
The stock valuation mechanism determines the current worth of Gain Therapeutics on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Gain Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Gain Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Gain Therapeutics's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Gain Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Gain Therapeutics. We calculate exposure to Gain Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Gain Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -25.2 K | -26.5 K | |
| Pretax Profit Margin | (402.11) | (382.00) | |
| Operating Profit Margin | (403.28) | (383.12) | |
| Net Loss | (403.54) | (383.37) | |
| Gross Profit Margin | (0.46) | (0.48) |
8 Steps to conduct Gain Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Gain Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Gain Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Gain Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Gain Therapeutics' revenue streams: Identify Gain Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Gain Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Gain Therapeutics' growth potential: Evaluate Gain Therapeutics' management, business model, and growth potential.
- Determine Gain Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Gain Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Gain Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Gain Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 13 M |
Gain Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Gain Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Gain we look at many different elements of the entity such as Gain's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Gain Therapeutics' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Gain Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Gain Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Gain Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Gain Therapeutics' worth.When determining whether Gain Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Gain Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Gain Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Gain Therapeutics Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Gain Stock analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
Is Gain Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gain Therapeutics. If investors know Gain will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gain Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.004 | Quarterly Revenue Growth (1.00) | Return On Assets (0.65) | Return On Equity (1.42) |
The market value of Gain Therapeutics is measured differently than its book value, which is the value of Gain that is recorded on the company's balance sheet. Investors also form their own opinion of Gain Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gain Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gain Therapeutics' market value can be influenced by many factors that don't directly affect Gain Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gain Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gain Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gain Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.